开云app官网登录入口网页版-官方正版

#NDA#

58篇内容 | 1597人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1581089, encodeId=dc53158108950, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=Fundamental Research：贺静团队综述神经母细胞瘤液体活检研究进展, objectType=article, longId=737163, objectId=fd98e37163a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd98e37163a7, replyNumber=0, likeNumber=78, createdTime=2022-08-29, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd98e37163a7, moduleTitle=Fundamental Research：贺静团队综述神经母细胞瘤液体活检研究进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fd98e37163a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581088, encodeId=c5551581088bf, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效, objectType=article, longId=293430, objectId=627129343025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=627129343025, replyNumber=0, likeNumber=90, createdTime=2022-01-06, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=627129343025, moduleTitle=Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=627129343025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581087, encodeId=5e20158108e26, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=美国阿南达医药科技（ANANDA Scientific）采用了Liquid Structure™技术的大麻二酚(CBD)将接受用于治疗阿片类用药障碍的临床评估, objectType=article, longId=218932, objectId=e31c21893241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e31c21893241, replyNumber=0, likeNumber=95, createdTime=2021-10-22, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e31c21893241, moduleTitle=美国阿南达医药科技（ANANDA Scientific）采用了Liquid Structure™技术的大麻二酚(CBD)将接受用于治疗阿片类用药障碍的临床评估, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e31c21893241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581086, encodeId=c92a158108621, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=ANANDA Scientific与加州大学洛杉矶分校David Geffen医学院宣布开展采用Liquid StructureTM大麻二酚(CBD)治疗阿片类用药障碍(OUD)的临床试验, objectType=article, longId=217999, objectId=3cbb21e9990e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cbb21e9990e, replyNumber=0, likeNumber=88, createdTime=2021-10-02, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cbb21e9990e, moduleTitle=ANANDA Scientific与加州大学洛杉矶分校David Geffen医学院宣布开展采用Liquid StructureTM大麻二酚(CBD)治疗阿片类用药障碍(OUD)的临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3cbb21e9990e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581085, encodeId=a0b51581085a0, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=ANANDA Scientific和纽约大学格罗斯曼医学院宣布，评估Liquid Structure™大麻二酚(CBD)治疗创伤后应激障碍(PTSD)的临床试验的首例患者已入组, objectType=article, longId=212608, objectId=8db421260828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8db421260828, replyNumber=0, likeNumber=91, createdTime=2021-06-13, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8db421260828, moduleTitle=ANANDA Scientific和纽约大学格罗斯曼医学院宣布，评估Liquid Structure™大麻二酚(CBD)治疗创伤后应激障碍(PTSD)的临床试验的首例患者已入组, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8db421260828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581084, encodeId=321a1581084c4, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=临床数据显示，Noxopharm的Veyonda®或可预防细胞因子风暴, objectType=article, longId=210640, objectId=47c62106408e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47c62106408e, replyNumber=0, likeNumber=69, createdTime=2021-05-01, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47c62106408e, moduleTitle=临床数据显示，Noxopharm的Veyonda®或可预防细胞因子风暴, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=47c62106408e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581083, encodeId=6bc7158108369, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=Noxopharm为Veyonda®申请败血症休克治疗专利, objectType=article, longId=210373, objectId=b1fe2103e3f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1fe2103e3f3, replyNumber=0, likeNumber=63, createdTime=2021-04-25, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1fe2103e3f3, moduleTitle=Noxopharm为Veyonda®申请败血症休克治疗专利, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b1fe2103e3f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581082, encodeId=e05b1581082f5, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=中国完全基于乐城真实世界研究数据申报NDA的新药OT-401（Yutiq）获NMPA受理, objectType=article, longId=209860, objectId=c7782098601b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7782098601b, replyNumber=0, likeNumber=77, createdTime=2021-04-14, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7782098601b, moduleTitle=中国完全基于乐城真实世界研究数据申报NDA的新药OT-401（Yutiq）获NMPA受理, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c7782098601b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581081, encodeId=46fd1581081a5, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=欧洲药品管理局：建议Saxenda用于治疗12至17岁青少年肥胖症, objectType=article, longId=209088, objectId=fbfe209088a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbfe209088a7, replyNumber=0, likeNumber=65, createdTime=2021-03-29, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbfe209088a7, moduleTitle=欧洲药品管理局：建议Saxenda用于治疗12至17岁青少年肥胖症, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fbfe209088a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581080, encodeId=831d15810805c, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=Br J Cancer：Mandard分级高：不代表食管腺癌对化疗无反应, objectType=article, longId=208932, objectId=7fa520893267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fa520893267, replyNumber=0, likeNumber=76, createdTime=2021-03-25, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fa520893267, moduleTitle=Br J Cancer：Mandard分级高：不代表食管腺癌对化疗无反应, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7fa520893267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581079, encodeId=872015810e9da, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=EORTC赞助的MINDACT研究试验在《柳叶刀·肿瘤学分册》上发表具有里程碑意义的长期数据, objectType=article, longId=208473, objectId=22c12084e366, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22c12084e366, replyNumber=0, likeNumber=73, createdTime=2021-03-18, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22c12084e366, moduleTitle=EORTC赞助的MINDACT研究试验在《柳叶刀·肿瘤学分册》上发表具有里程碑意义的长期数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=22c12084e366)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581078, encodeId=d4d115810e8fc, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA, objectType=article, longId=205086, objectId=4d4920508636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d4920508636, replyNumber=0, likeNumber=71, createdTime=2021-01-02, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d4920508636, moduleTitle=中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4d4920508636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581077, encodeId=406f15810e723, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=LORBRENA（lorlatinib）治疗先前未经治疗的ALK阳性肺癌的sNDA已被美国FDA接受优先审查, objectType=article, longId=204976, objectId=72d72049e6db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72d72049e6db, replyNumber=0, likeNumber=68, createdTime=2020-12-31, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72d72049e6db, moduleTitle=LORBRENA（lorlatinib）治疗先前未经治疗的ALK阳性肺癌的sNDA已被美国FDA接受优先审查, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=72d72049e6db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581076, encodeId=313a15810e601, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者, objectType=article, longId=202449, objectId=39aa20244938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39aa20244938, replyNumber=0, likeNumber=76, createdTime=2020-10-26, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39aa20244938, moduleTitle=FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=39aa20244938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581075, encodeId=997c15810e570, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=FDA授予Avacopan治疗ANCA相关性血管炎的新药申请（NDA）, objectType=article, longId=200910, objectId=479020091084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=479020091084, replyNumber=0, likeNumber=78, createdTime=2020-09-20, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=479020091084, moduleTitle=FDA授予Avacopan治疗ANCA相关性血管炎的新药申请（NDA）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=479020091084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581074, encodeId=253615810e496, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=支架术后没有“吸烟悖论”，烟民心梗比例高！乔树宾等PANDA Ⅲ临床试验, objectType=article, longId=195318, objectId=40d419531812, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40d419531812, replyNumber=0, likeNumber=70, createdTime=2020-06-06, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40d419531812, moduleTitle=支架术后没有“吸烟悖论”，烟民心梗比例高！乔树宾等PANDA Ⅲ临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=40d419531812)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581073, encodeId=05f415810e3b3, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=复发难治肾细胞癌的治疗或迎新突破：FDA已批准Tivozanib的NDA, objectType=article, longId=195152, objectId=4ee01951523a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ee01951523a, replyNumber=0, likeNumber=83, createdTime=2020-06-04, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ee01951523a, moduleTitle=复发难治肾细胞癌的治疗或迎新突破：FDA已批准Tivozanib的NDA, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4ee01951523a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581072, encodeId=7b8015810e279, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=Ponesimod治疗成人多发性硬化症：强生已向美国FDA提交新药申请（NDA）, objectType=article, longId=190437, objectId=1dee19043e93, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dee19043e93, replyNumber=0, likeNumber=79, createdTime=2020-03-21, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dee19043e93, moduleTitle=Ponesimod治疗成人多发性硬化症：强生已向美国FDA提交新药申请（NDA）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1dee19043e93)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581071, encodeId=b85015810e180, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=膀胱过度活动症的治疗取得新进展！FDA接受Vibegron的新药申请（NDA）, objectType=article, longId=189501, objectId=f83118950156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f83118950156, replyNumber=0, likeNumber=83, createdTime=2020-03-08, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f83118950156, moduleTitle=膀胱过度活动症的治疗取得新进展！FDA接受Vibegron的新药申请（NDA）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f83118950156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581070, encodeId=6f2415810e05a, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, objectTitle=辉瑞的Vyndaqel首次在欧洲获批用于治疗淀粉样变心肌病ATTR-CM, objectType=article, longId=188474, objectId=ccaa1884e403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccaa1884e403, replyNumber=0, likeNumber=88, createdTime=2020-02-22, rootId=0, userName=12498a49m65暂无昵称, userId=9a9e16702381, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccaa1884e403, moduleTitle=辉瑞的Vyndaqel首次在欧洲获批用于治疗淀粉样变心肌病ATTR-CM, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ccaa1884e403)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

NDA

2020-05-29

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

Fundamental Research：贺静团队综述神经母细胞瘤液体活检研究进展

2022-08-29

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效

2022-01-06

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

美国阿南达医药科技（ANANDA Scientific）采用了Liquid Structure™技术的大麻二酚(CBD)将接受用于治疗阿片类用药障碍的临床评估

2021-10-22

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

ANANDA Scientific与加州大学洛杉矶分校David Geffen医学院宣布开展采用Liquid StructureTM大麻二酚(CBD)治疗阿片类用药障碍(OUD)的临床试验

2021-10-02

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

ANANDA Scientific和纽约大学格罗斯曼医学院宣布，评估Liquid Structure™大麻二酚(CBD)治疗创伤后应激障碍(PTSD)的临床试验的首例患者已入组

2021-06-13

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

临床数据显示，Noxopharm的Veyonda®或可预防细胞因子风暴

2021-05-01

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

Noxopharm为Veyonda®申请败血症休克治疗专利

2021-04-25

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

中国完全基于乐城真实世界研究数据申报NDA的新药OT-401（Yutiq）获NMPA受理

2021-04-14

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

欧洲药品管理局：建议Saxenda用于治疗12至17岁青少年肥胖症

2021-03-29

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

Br J Cancer：Mandard分级高：不代表食管腺癌对化疗无反应

2021-03-25

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

EORTC赞助的MINDACT研究试验在《柳叶刀·肿瘤学分册》上发表具有里程碑意义的长期数据

2021-03-18

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA

2021-01-02

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

LORBRENA（lorlatinib）治疗先前未经治疗的ALK阳性肺癌的sNDA已被美国FDA接受优先审查

2020-12-31

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者

2020-10-26

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

FDA授予Avacopan治疗ANCA相关性血管炎的新药申请（NDA）

2020-09-20

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

支架术后没有“吸烟悖论”，烟民心梗比例高！乔树宾等PANDA Ⅲ临床试验

2020-06-06

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

复发难治肾细胞癌的治疗或迎新突破：FDA已批准Tivozanib的NDA

2020-06-04

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

Ponesimod治疗成人多发性硬化症：强生已向美国FDA提交新药申请（NDA）

2020-03-21

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

膀胱过度活动症的治疗取得新进展！FDA接受Vibegron的新药申请（NDA）

2020-03-08

12498a49m65暂无昵称 (审核中...)

前往app查看评论内容

#NDA#

辉瑞的Vyndaqel首次在欧洲获批用于治疗淀粉样变心肌病ATTR-CM

2020-02-22

科室
- - 订阅+
  - 更多科室
工具
服务